Trial Profile
Randomised phase II study with cetuximab (Erbitux) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CETMET
- 05 May 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 07 Sep 2020 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 05 Jun 2018 Results evaluating efficacy and safety of cetuximab (n=85) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology